Codex DNA Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 133
Employees
  • Stock Symbol
  • DNAY
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $8.32
  • (As of Monday Closing)

Codex DNA General Information

Description

Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.

Contact Information

Formerly Known As
SGI-DNA
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 9535 Waples Street
  • Suite 100
  • San Diego, CA 92121-2993
  • United States
+1 (858) 000-0000

Codex DNA Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Codex DNA Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.32 $9.13 $6.16 - $25.70 $268M 29.3M 609K -$2.07

Codex DNA Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 219,989
Revenue 9,902 6,576 4,805
EBITDA (29,389) (15,858)
Net Income (32,050) (18,010)
Total Assets 124,494 26,863 38,761
Total Debt 15,601 8,326 4,768
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Codex DNA Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Codex DNA‘s full profile, request access.

Request a free trial

Codex DNA Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Codex DNA‘s full profile, request access.

Request a free trial

Codex DNA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly bu
Discovery Tools (Healthcare)
San Diego, CA
133 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag
0000 000000000
Menlo Park, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
San Diego, CA
00 As of 0000
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Codex DNA Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Personalis Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed San Diego, CA 00 000.00 0000000000 000.00
00000000000 Corporate Backed or Acquired Bothell, WA 000000&0
00000 0000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 000000 00 Formerly VC-backed Baltimore, MD 000 00000 000000&0 00000
You’re viewing 5 of 8 competitors. Get the full list »

Codex DNA Patents

Codex DNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210277446-A1 Methods for assembling nucleic acids Pending 03-Mar-2020 0000000000
US-20210284954-A1 Vibrio sp. organisms with modified lipopolysaccharide Pending 20-Nov-2017 000000000
CA-3082589-A1 Vibrio sp. organisms with modified lipopolysaccharide Pending 20-Nov-2017 000000000
AU-2018367359-A1 Vibrio sp. organisms with modified lipopolysaccharide Pending 20-Nov-2017 000000000
US-20190153554-A1 Vibrio sp. organisms with modified lipopolysaccharide Granted 20-Nov-2017 C12R1/63 0
To view Codex DNA’s complete patent history, request access »

Codex DNA Executive Team (8)

Name Title Board Seat Contact Info
Todd Nelson Ph.D Chief Executive Officer & Board Member
Jennifer McNealey Chief Financial Officer, Finance
Justin Emory Vice President
Madoo Varma Vice President
Daniel Gibson Ph.D Chief Technology Officer, Technology
You’re viewing 5 of 8 executive team members. Get the full list »

Codex DNA Board Members (8)

Name Representing Role Since
Andrea Jackson Northpond Ventures Board Member 000 0000
Andrew Lee Ph.D Northpond Ventures Board Director 000 0000
Christine Tsingos Codex DNA Board Member 000 0000
Frank Witney Ph.D Self Board Member 000 0000
Jami Nachtsheim Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Codex DNA Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Codex DNA Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Codex DNA‘s full profile, request access.

Request a free trial

Codex DNA Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 09-Nov-2021 0000000000 0000 Biotechnology 0000 0000
To view Codex DNA’s complete acquisitions history, request access »